B Group, Inc.
Sector Allocation
- Healthcare91.3%$160.9M
- Other8.7%$15.3M
AUM History
13fpro.ai/research/fund/b-group-inc-2043476
Conviction and streaks
Diversifying · top 10 = 79.2%From the fund's last 12 quarters of 13F filings: positions held longest at size, and names it added to or trimmed several quarters running.
Largest positions — Q2 2026
ADMA
$27.3MPALI
$23.9MNRXP
$16.7M- FAETH$15.3M
TSHA
$12.3MPRAX
$11.1MCLLS
$9.8MZLAB
$8.6MGPCR
$7.5MORKA
$7.1MIOVA
$6.2MSYRE
$6.2MAURA
$5.4MASMB
$4.8MDRUG
$4.7MRARE
$4.5MSGHT
$3.7MFHTX
$976K
Top 20 stock positions. Options are left out: 13F reports them at the underlying's value.
13fpro.ai/research/fund/b-group-inc-2043476
B Group, Inc. 13F holdings — Q2 2026
$213.0M portfolio (+57.9% QoQ) · 19 holdings · Q2 2026 13F · top 10 are 79% of the stock portfolio
Includes $36.8M of put/call options ($36.8M puts, $0 calls), which 13F rules report at the value of the underlying shares, not the premium at risk. Stocks alone: $176.2M. Weights use the stock portfolio.
$27.3M
15.5% of stocks
+2%This quarter+16.8%Since filed7+ qtrsHeld$23.9M
13.5% of stocks
No changeThis quarter-42.5%Since filed3 qtrsHeld$16.7M
9.5% of stocks
+36%This quarter-22.0%Since filed2 qtrsHeld- 4
FAETH THERAPEUTICS INC - COM NEW
$15.3M
8.7% of stocks
NewThis quarter—Since filedNew this quarterHeldAIQuality—Est. buy— $12.3M
7.0% of stocks
No changeThis quarter-32.6%Since filed7+ qtrsHeld$11.1M
6.3% of stocks
No changeThis quarter-27.1%Since filed6 qtrsHeld$9.8M
5.6% of stocks
No changeThis quarter-68.3%Since filed7+ qtrsHeld$8.6M
4.9% of stocks
No changeThis quarter-6.0%Since filed7+ qtrsHeld$7.5M
4.3% of stocks
+10%This quarter-61.3%Since filed3 qtrsHeldAIQualityAI quality score is Pro: unlock with a free trialEst. buyEstimated buy price is Pro: unlock with a free trialAdded 3 qtrs in a row$7.1M
4.0% of stocks
No changeThis quarter-18.6%Since filed7+ qtrsHeld
All holdings — B Group, Inc. (Q2 2026)
19 disclosed positions from the Form 13F-HR on SEC EDGAR, with quarter-over-quarter share changes. Largest by value first; the ten above are not repeated.
| # | Company | Held | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 11 | INVESCO QQQ TRUST, SERIES 1 | — | $36.8M | — | 50K | New | — | — | 13F | |
| 12 | IOVANCE BIOTHERAPEUTICS, INC. | Healthcare | $6.2M | 3.5% | 1.50M | — | 7+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 13 | Spyre Therapeutics, Inc. | Healthcare | $6.2M | 3.5% | 70K | -30% | 7+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 14 | Aura Biosciences, Inc. | Healthcare | $5.4M | 3.1% | 764K | +28% | 7+ qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F | |
| 15 | ASSEMBLY BIOSCIENCES, INC. | Healthcare | $4.8M | 2.7% | 176K | — | 7+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 16 | BRIGHT MINDS BIOSCIENCES INC. | Healthcare | $4.7M | 2.7% | 68K | — | 2 qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 17 | Ultragenyx Pharmaceutical Inc. | Healthcare | $4.5M | 2.6% | 135K | — | 7+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 18 | Sight Sciences, Inc. | Healthcare | $3.7M | 2.1% | 970K | — | 7+ qtrs | AI quality score is Pro: unlock with a free trial | 13F | |
| 19 | Foghorn Therapeutics Inc. | Healthcare | $976K | 0.6% | 200K | +96% | 2 qtrsAdded 2 qtrs in a row | AI quality score is Pro: unlock with a free trial | 13F |
What changed in Q2 2026
Against the previous quarter's 13F: 2 new, 5 added to, 1 trimmed, 3 sold out. Share-count changes; largest moves by dollar size first.
New positions (2)
$QQQPUTINVESCO QQQ TRUST, SERIES 1$36.8M
first bought this quarter
- FAETH THERAPEUTICS INC - COM NEW$15.3M
first bought this quarter
Added to (5)
now $16.7M · held 2 qtrs, 2 adds in a row
now $5.4M · held 7+ qtrs, 2 adds in a row
now $7.5M · held 3 qtrs, 3 adds in a row
now $976K · held 2 qtrs, 2 adds in a row
now $27.3M · held 7+ qtrs, 4 adds in a row
Trimmed (1)
now $6.2M · held 7+ qtrs
Holdings by quarter
Every 13F B Group, Inc. has filed, 6 earlier quarters. Pick one to see what it held then.
Is it too late to follow B Group?
Q2 2026 13F filed with the SEC on Aug 14, 2026. Prices are closing prices as of Oct 26, 2026.
Average quality of B Group's top 20 holdings: 44/100 (our AI quality score, weighted by position size; 7 of the 20 are scored)
Top 10 since filing
-17.9%
Value-weighted move of the 10 largest stock positions
Turnover
2%
Last quarter; 24% over the last 4
Top 10 weight
79%
Share of the stock portfolio in its 10 largest positions
Held 4+ quarters
67%
Share of portfolio value in positions held a year or more
Highest-quality names it owns(among its 100 largest positions)
The 7 highest-scoring companies in this portfolio are a Pro feature.
How these are measured
- Moves since the quarter-end and since the filing date use our own daily closing prices, from the close on (or just before) each date to the latest close.
- Turnover is the lesser of shares bought or sold in a quarter, valued at the quarter-end prices in the 13F, divided by the average of the two quarters' stock portfolio values.
- Quarters held and add/trim streaks count back only through quarters whose filed holdings add up to the filing's own cover-page total (back to Q4 2024 for this fund). A change counts as an add or a trim when the split-adjusted share count moves by more than 1%.
- Estimate, not the fund's reported cost. For each quarter in the current holding period in which the fund's share count rose (split-adjusted), we take that quarter's average daily close and weight it by the shares added; sales do not change an average cost. Quarters where the stock's price history and the 13F's own implied price disagree by more than 2x are left out.
- Put and call option rows report the value of the underlying shares, not a position the fund paid for, so they are left out of all of the above.
Portfolio Overview
B Group, Inc. disclosed 19 positions worth $213.0M in its Form 13F-HR for Q2 2026 — $176.2M in common stock plus $36.8M of put/call option positions (reported at underlying notional value, not premium at risk), led by $ADMA (ADMA BIOLOGICS, INC.) at 15.5% of the equity portfolio, followed by $PALI and $NRXP. During the quarter the fund opened 2 new positions and exited 3 — including a new stake in $QQQ and a full exit from $APGE. The portfolio is most concentrated in Healthcare (91.3% of disclosed assets). All figures are sourced directly from B Group, Inc.’s Form 13F-HR filing with the SEC under CIK 2043476.
Funds like this
managers whose biggest positions overlap B Group'sBrowse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
AI-Powered Hedge Fund Analysis: B Group, Inc.
13F Pro is an AI hedge fund tracker and stock research platform. For B Group, Inc. (SEC CIK: 2043476), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in B Group, Inc.'s portfolio is scored on an AI quality ranking built from its SEC filings (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.